Moacyr Bighetti

About Moacyr

Moacyr Bighetti is the founder of PHP Biotech and a member of its Executive Committee. He is a pharmaceutical R&D entrepreneur with a roughly 20-year track record of translating laboratory innovation into protected, licensable, globally deployed products.

Bighetti is the CEO of Kaivo Biotech, a Brazilian developer of biological products for human and veterinary health. His inventive output is substantial: he is credited with more than nine patents, several filed across more than 40 countries — a signal both of technical originality and of a disciplined intellectual-property strategy, which is essential for a platform company whose value rests on defensible, first-in-class assets. His work has also led to the licensing of products to major pharmaceutical companies including Bayer Healthcare and Sanofi across more than 20 countries.

That combination — invention, patenting, and international licensing — is precisely the founder profile a nanobody platform company needs. PHP Biotech’s thesis depends not only on the PHP53-nb lead candidate but on the reusability of the GEN01-AD delivery platform across multiple future payloads and indications. Bighetti’s experience protecting and commercializing pharmaceutical IP globally directly informs how that platform is structured, protected, and partnered.

As founder, Bighetti provides continuity of scientific and strategic vision, bridging the origin of the science at Kaivo Biotech with PHP Biotech’s forward development and its executive committee’s oversight of partnerships and long-term direction.